News

PrognoCIS enables physicians to qualify for federal funding to assist with EMR costs. PrognoCIS EMR system features system-level and encounter-level dashboards and helps track and monitor the customer’s

With this application, the doctors can view critical laboratory, pathology and radiology results, demographics, notes, patient lists and trending data from multiple sources and render informed decisions via

Under the agreement, TS Pharma will commercialize the product in Antigua, Aruba, Bahamas, Barbados, Belize, Bermuda, Cayman Islands, Costa Rica, Curacao, , Dominican Republic, Guatemala, Haiti, Honduras, Jamaica,

The 24-week randomized placebo-controlled, double-blind, multi-center Impres trial involving 202 patients is intended to evaluate the efficacy and safety of oral QTI571 as an add-on therapy in the

The Belief registration trial is a multicenter, open-label, single arm efficacy and safety study in patients with relapsed or refractory PTCL, who have failed at least one prior

Under the contract, the companies will work on drug metabolism and pharmacokinetics studies, including CYP inhibition, metabolic identification and stability. It will also include metabolic identification and stability,

Initially, the company will get around $17m over 18 months from BARDA to ramp up the development of HemaMax. Additional financing over the next 3.5 years is available

Hartmanis held leadership positions in Gambro, Amersham and Pharmacia and was appointed as CEO of the specialty pharmaceutical company BioPhausia in 2010. Medivir chairman of the board Goran

The filing of the application is backed by the results of a double-blind study (Hopeful1 Study) which included around 334 rheumatoid arthritis patients and received concomitant treatment using